- Monoclonal antibody directed at alpha-4-beta-7 integrin
- Used to treat inflammatory bowel disease
- Low risk of opportunistic infections1
- Clostridioides difficile
- CMV infections
- Esophageal candidiasis
References
- ^ Siew C Ng, Ida Normiha Hilmi, Aimee Blake, Fatima Bhayat, Shashi Adsul, Qasim Rana Khan, Deng-Chyang Wu. Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflammatory Bowel Diseases. 2018;24(11):2431-2441. doi:10.1093/ibd/izy153.
